SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer

被引：0
|
作者：
Montal, R. [1 ]
Merche, M. -V. [1 ]
Anta, B. [2 ]
Martinez, N. [2 ]
Santos, C. [1 ,3 ]
Sanjuan, X. [4 ]
Paules, M. J. [5 ]
Perez Martin, F. J. [6 ]
Azuara, D. [3 ]
Salazar, R. [1 ,3 ]
Rojas, J. M. [2 ]
机构：
[1] Inst Catala Oncol IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
[2] Inst Salud Carlos III UFIEC, Majadahonda, Spain
[3] Inst Catala Oncol IDIBELL, Translat Res Lab, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Lhospitalet De Llobregat, Spain
[5] HUB, IDIBELL, Interdisciplinary Comm Esophagogastr Tumours, Lhospitalet De Llobregat, Spain
[6] Inst Catala Oncol ICO LHospitalet, IDIBELL, Clin Res Unit, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-195
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Epigenetic DNA Modifications Upregulate SPRY2 in Human Colorectal Cancers
    Stuckel, Alexei J.
    Zeng, Shuai
    Lyu, Zhen
    Zhang, Wei
    Zhang, Xu
    Dougherty, Urszula
    Mustafi, Reba
    Zhang, Qiong
    Joshi, Trupti
    Bissonnette, Marc
    Choudhury, Samrat Roy
    Khare, Sharad
    CELLS, 2021, 10 (10)
  • [12] QUANTITATIVE MEASUREMENT OF KRAS MUTATED ALLELES IN PLASMA AS PROGNOSTIC MARKER IN METASTATIC KRAS MUTANT COLORECTAL CANCER
    Spindler, K.
    Pallisgaard, N.
    Andersen, R.
    Jakobsen, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 530 - 531
  • [13] Spry2 expression correlates with BRAF mutation in thyroid cancer
    Xu, Lizhong
    Zhou, Jun Liang
    Cohen, Michael
    Bar-Sagi, Dafna
    Patel, Kepal N.
    SURGERY, 2010, 148 (06) : 1282 - 1287
  • [14] Kras in metastatic colorectal cancer
    Wicki, Andreas
    Herrmann, Richard
    Christofori, Gerhard
    SWISS MEDICAL WEEKLY, 2010, 140 : 14 - 19
  • [15] CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
    Aasebo, Kristine
    Dragomir, Anca
    Sundstrom, Magnus
    Mezheyeuski, Artur
    Edqvist, Per-Henrik
    Eide, Geir Egil
    Ponten, Fredrik
    Pfeiffer, Per
    Glimelius, Bengt
    Sorbye, Halfdan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [16] KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
    Y Kawamoto
    K Tsuchihara
    T Yoshino
    N Ogasawara
    M Kojima
    M Takahashi
    A Ochiai
    H Bando
    N Fuse
    M Tahara
    T Doi
    H Esumi
    Y Komatsu
    A Ohtsu
    British Journal of Cancer, 2012, 107 : 340 - 344
  • [17] KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
    Kawamoto, Y.
    Tsuchihara, K.
    Yoshino, T.
    Ogasawara, N.
    Kojima, M.
    Takahashi, M.
    Ochiai, A.
    Bando, H.
    Fuse, N.
    Tahara, M.
    Doi, T.
    Esumi, H.
    Komatsu, Y.
    Ohtsu, A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (02) : 340 - 344
  • [18] Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
    Hoff, Paulo M.
    Hochhaus, Andreas
    Pestalozzi, Bernhard C.
    Tebbutt, Niall C.
    Li, Jin
    Kim, Tae Won
    Koynov, Krassimir D.
    Kurteva, Galina
    Pinter, Tamas
    Cheng, Ying
    van Eyll, Brigitte
    Pike, Laura
    Fielding, Anitra
    Robertson, Jane D.
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3596 - 3603
  • [19] Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
    Chua, W.
    Goldstein, D.
    Lee, C. K.
    Dhillon, H.
    Michael, M.
    Mitchell, P.
    Clarke, S. J.
    Iacopetta, B.
    BRITISH JOURNAL OF CANCER, 2009, 101 (06) : 998 - 1004
  • [20] Combined KRAS and TP53 Mutation Status Is Not Predictive in CAPOX-treated Metastatic Colorectal Cancer
    De Bruijn, Menno T.
    Raats, Danielle A. E.
    Tol, Jolien
    Hinrichs, John
    Teerenstra, Steven
    Punt, Cornelis J. A.
    Rinkes, Inne H. M. Borel
    Kranenburg, Onno
    ANTICANCER RESEARCH, 2011, 31 (04) : 1379 - 1385
12345